USA flag logo/image

An Official Website of the United States Government

Not Available

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96437
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
N43CO201000125
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Not Available
Agency: HHS
Contract: N43CO201000125
Award Amount: $150,000.00
 

Abstract:

Quantum dots (ODs) with unique optical properties such as size-tunable emission , simultaneous excitation,  high brightness, and very slow photobleaching ¿can be used as powerful cancer diagnostic tools providing the  -"'¿cile-cular¿ profiles of cancer cases based on common clinical biopsies and allowing the tumor cell detection  ¿and-analysis in highly heterogenous samples and rare cell populations. However, researchers have found  that the¿ fluorescence intensity of QDs changes under light irradiation and the QD-antibody conjugates  detaches from tissues easily during the staining process, making it very difficult to quantify expression level  of biomarkers. To develop QD based multiplexing and quantitative kits for clinical applications, this team  proposes to increase the QD stability through the multi-shell coating strategy in Aim 1 and to develop the  high-bioaffinity QD-Antibody (Ab) through the adaptor protein strategy in Aim 2. As the first application, the  improved QO-Ab technology will be used to develop a multi-biomarker imaging kit for prediction of human  papilomavirus (HPV)- associated cancer. HPV is one of the risk factors in cancer development. Accurate  evaluation of the impact of HPV on cancer development requires incorporation of our knowledge of the  pathways by which HPV causes cancer. This team would like to use three QD-conjugated antibodies which  specifically bind to HPV-related proteins as a predictor for cancer assessment. As a preparation for the  phase II development of this technology, Aim 3 and 4 will validate Ihe HPV specific QD-Abs and oplimize Ihe  condition for multiple QD-staining and quantification, respectively, by using human cancer cell lines and  tissues.

Principal Investigator:

Y. andrew Wang
(479) 236-7147
AWANG@OCEANNANOTECH.COM
Small Business Information at Submission:

OCEAN NANOTECH, LLC
2143 Worth Lane SPRINGDALE, AR 72764-

EIN/Tax ID: 270097569
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No